Oracle stock is down after earnings miss and elevated cloud expectations
The software giant reported $4.21 billion in profit, or $1.47 per share, for the three months that ended in late November.
The software giant reported $4.21 billion in profit, or $1.47 per share, for the three months that ended in late November.
Tesla shares have added nearly $450 billion in market value since Election Day.
Bond markets are likely to be in focus today with the first of three major coupon auctions that will raise around $120 billion for the U.S. Treasury
A supplier of world cuisine, Surya Foods' best-known branded products include Laila rice and Thai Dragon condiments.
Money market account interest rates today are well above historical norms. Find out where to get the best MMA rates.
Increasing chaos in the Middle East usually brings an oil shock with it – but we also have an incoming second Trump administration, one that is likely to push for an expansion of American domestic oil production. How these currents will interact is difficult to predict, but the oil industry experts at JPMorgan have some insights into the situation. In short, the bank sees likely strength on the exploration and production side of the US oil industry, from a combination of improved efficiencies in
Broadcom will report fourth-quarter earnings after the market closes on Thursday, and analysts are pretty uniformly bullish on the semiconductor manufacturer.
(Reuters) -Oracle's second-quarter revenue grew less than Wall Street expected on Monday, hit by stiff competition among database and cloud services providers, sending its shares down more than 7% in extended trading. While seeing healthy growth in its cloud segment, Oracle competes with cloud heavyweights such as Microsoft and Amazon, which have established a large presence in the field. Wall Street expectations for AI-linked firms have been high as they bet on the technology to be a strong growth driver in the future.
One of the UK’s leading blue-chip companies is preparing to shift its listing from London to New York, dealing yet another blow to Britain’s beleaguered stock market.
GSK’s cancer drug failed a confirmatory trial two years after an accelerated approval, but impressive new survival data could change the tide.